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AbSTRACT
Introduction Patients with head and neck squamous cell 
carcinoma with locally advanced disease often require 
multimodality treatment with surgery, radiotherapy and/
or chemotherapy. Adjuvant radiotherapy with concurrent 
chemotherapy is offered to patients with high- risk 
pathological features postsurgery. While cure rates 
are improved, overall survival remains suboptimal and 
treatment has a significant negative impact on quality of 
life.
Cell cycle checkpoint kinase inhibition is a promising 
method to selectively potentiate the therapeutic effects 
of chemoradiation. Our hypothesis is that combining 
chemoradiation with a WEE1 inhibitor will affect the 
biological response to DNA damage caused by cisplatin 
and radiation, thereby enhancing clinical outcomes, 
without increased toxicity. This trial explores the 
associated effect of WEE1 kinase inhibitor adavosertib 
(AZD1775).
Methods and analysis This phase I dose- finding, open- 
label, multicentre trial aims to determine the highest 
safe dose of AZD1775 in combination with cisplatin 
chemotherapy preoperatively (group A) as a window of 
opportunity trial, and in combination with postoperative 
cisplatin- based chemoradiation (group B).
Modified time- to- event continual reassessment method 
will determine the recommended dose, recruiting up to 21 
patients per group. Primary outcomes are recommended 
doses with predefined target dose- limiting toxicity 
probabilities of 25% monitored up to 42 days (group A), 
and 30% monitored up to 12 weeks (group B). Secondary 
outcomes are disease- free survival times (groups A and B). 
Exploratory objectives are evaluation of pharmacodynamic 
(PD) effects, identification and correlation of potential 
biomarkers with PD markers of DNA damage, determine 
rate of resection status and surgical complications for 
group A; and quality of life in group B.
Ethics and dissemination Research Ethics Committee, 
Edgbaston, West Midlands (REC reference 16/WM/0501) 
initial approval received on 18/01/2017. Results will 
be disseminated via peer- reviewed publication and 
presentation at international conferences.
Trial registration number ISRCTN76291951 and 
NCT03028766.
InTRoduCTIon
Head and neck cancers are the sixth most 
common cancer worldwide,1 with 12 000 new 
cases per year in the UK (Cancer Research 
UK (CRUK) head and neck cancer statistics). 
The most common types are head and neck 
squamous cell carcinom (HNSCC) arising 
from laryngeal, oral cavity, oropharynx and 
hypopharyngeal subsites.2
Strengths and limitations of this study
 ► The study is one of the first to explore a WEE1 inhib-
itor in combination with cisplatin and radiotherapy, 
and the first to do so in head and neck cancer.
 ► Allows collection of tissues for translational research 
to examine the pharmacodynamic effects of WEE1 
and WEE1 in combination with cisplatin.
 ► Uses an efficient time- to- event continual reas-
sessment method design which allows dose as-
signments to be performed with the flexibility of 
continual patient accrual or temporary accrual sus-
pension to permit sufficient accumulation of safety 
information as necessary.
 ► Additional biopsies in the preoperative setting may 
affect the patient enrolment.
 ► The oral administration of AZD1775 may affect re-
cruitment in postoperative patients if they have diffi-
culty or are unable to swallow.
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Primary surgery is the standard of care for cancers of the 
oral cavity, and for more advanced cancers of the larynx 
and hypopharynx, while chemoradiation is the stan-
dard approach to oropharyngeal disease. Postoperative 
radiotherapy (PORT) or postoperative chemoradiation 
(POCRT) is often recommended in the setting of high- 
risk features such as a positive margin, multiple involved 
nodes, extracapsular spread and perineural infiltration.
The role of concomitant chemotherapy was established 
by the Meta- Analysis of Chemotherapy on Head and Neck 
Cancer in 2009.2 This study pooled individual patient data 
from 93 trials involving 16 485 patients receiving either 
definitive local therapy alone (surgery or radiotherapy) 
or local therapy plus chemotherapy (induction, concom-
itant or adjuvant). Concomitant therapy was assessed in 
50 trials involving 9605 patients; chemotherapy decreased 
the risk of death with an HR of 0.81, translating into a 
6.5% overall survival advantage at 5 years as a result of 
improved disease- free survival. No benefit was seen in 
patients aged over 70 years. This provides robust evidence 
that the ability of radiotherapy to secure local control can 
be enhanced by systemic therapy.
Acute toxicity and long- term sequelae of POCRT 
have a considerable negative health impact, and despite 
intensive treatment, 5- year overall survival is suboptimal 
at 53%.3 Locoregional relapse is particularly difficult to 
salvage, and local control is, therefore, closely correlated 
with overall survival. Morbidity imposed by local recur-
rence in the absence of distant metastatic disease is 
considerable and can be extremely challenging to palliate 
adequately. There is an urgent need to develop novel 
approaches that achieve improved locoregional disease 
control and reduce treatment- related morbidity for this 
patient group. Achieving this may translate into improved 
overall survival and an enhancement in patient- related 
outcome measures.
Chemotherapy, radiotherapy and dnA damage response
Cellular DNA damage response (DDR) is central to the 
preservation of genomic integrity. Cancer development 
is a multistep process where deregulation of the DDR 
contributes to phenotypes such as sustained cell prolif-
eration and resistance to cell death. This increase in 
endogenous DNA damage necessitates the acquisition 
of compensatory mechanisms if the cell is to avoid death 
through uncontrolled genomic instability. Importantly, 
these compensatory changes may constitute a molecular 
‘Achilles heel’ that is vulnerable to therapeutic exploita-
tion with a new generation of targeted agents. POCRT 
exploits the differential DDR in malignant and normal 
tissues to eradicate microscopic residual disease. Ionising 
radiation (IR) generates a variety of biological changes 
within irradiated tissue, with double- stranded DNA 
(dsDNA) breaks being therapeutically significant. IR- in-
duced cell death is also immunogenic, with recruitment 
of immune effectors to the irradiated tumour microenvi-
ronment contributing to a successful outcome.4 Platinum- 
based chemotherapy accentuates IR- induced cell death, 
in part via the suppression of homologous recombina-
tion, the primary repair mechanism for dsDNA damage 
in irradiated cells.4 Manipulation of the DDR pathway, 
therefore, represents a rational means by which the 
therapeutic index of POCRT might be improved. Cell 
cycle checkpoints are integral components of the DDR, 
allowing the cell to pause progression through the cell 
cycle to repair DNA damage. Checkpoints are regulated 
by a network of phosphorylation cascades. p53, encoded 
by TP53, is a key regulator of the G1/S checkpoint. TP53 
mutations, which are seen in 60%–70% of HNSCC cases,5 
are sufficient to impair the function of this checkpoint 
and thereby create a critical reliance on the later G2/M 
checkpoint. In addition, p53 function can be inactivated 
by various mechanisms, including somatic and germline 
mutations as well as polymorphisms.6 7
Pharmacological abrogation of the G2/M checkpoint 
has been shown to differentially sensitise normal and 
tumour cells to the effect of DNA damaging agents such 
as cisplatin and IR.8
WEE1 kinase and AZd1775
WEE1 kinase is a key regulator of the G2/M checkpoint 
and a promising therapeutic target. It is a serine- threonine 
kinase involved in phosphorylation and inactivation of 
cyclin- dependent kinase 1 (CDK1), the only 1 of 14 similar 
proteins to be indispensable for mitotic entry. Along with 
a number of other proteins, WEE1 triggers G2/M arrest 
in response to DNA damage. However, inhibition of 
WEE1 leads to high CDK1 activity, allowing cells to prog-
ress through the G2/M checkpoint without the oppor-
tunity to repair damaged DNA, leading to potentially 
catastrophic levels of unrepaired DNA damage induc-
tion of cell death.9 10 WEE1 also has an effect on CDK2 
as its inhibition leads to high CDK2 activity and aberrant 
DNA replication, resulting in stalled replication forks 
and DNA double- stranded breaks. WEE1 upregulation is 
seen in a variety of human cancers and is inversely asso-
ciated with prognosis in some models.11 12 Two separate 
kinomic screens in HNSCC identified WEE1 expression 
as a particularly strong determinant of cell survival,13 14 
indicating that HNSCC may be a fruitful setting in which 
to investigate the clinical effects of WEE1 inhibition.
Adavosertib (AZD1775) is a potent, selective small 
molecule inhibitor of WEE1. It has been shown to poten-
tiate the activity of various chemotherapeutic agents in 
vitro and in vivo. Some studies suggest the sensitising 
effect is only seen in p53- deficient tumours14–16 although 
not exclusively.10 It has also been shown to enhance IR- in-
duced cell death in TP53- mutant cell lines.
Coexposure of AZD1775 and cisplatin were found to 
reduce clonogenic survival,17 demonstrating this combi-
nation therapy has the ability to overcome cisplatin resis-
tance in HNSCC. Similar effects of this compound on 
radiation- induced cell death have been seen in models of 
typically radio- resistant cancer, such as pontine glioma,18 
glioblastoma19 and pancreatic adenocarcinoma.20 Impor-
tantly, one study has shown that WEE1 inhibition by 
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AZD1775 sensitises acute myelogenous leukaemia and 
lung cancer cell lines to cytarabine chemotherapy inde-
pendently of p53 status,10 suggesting that p53 mutation 
as a predictive biomarker for response to WEE1 inhibi-
tion may be cancer and/or chemotherapy specific. WEE1 
has also been implicated in maintaining genomic stability 
through stabilisation of replication forks—downregula-
tion reduces replication fork speed during S- phase, gener-
ating potentially lethal dsDNA breaks.21 By impacting 
both cell cycle progression and DNA damage repair, 
WEE1 inhibition may potentiate cell death in response to 
chemotherapy and IR. This suggests that there may be an 
additive effect on clinical outcome in combination with 
POCRT, as well as potential synergy.
AZD1775 is being tested in many clinical settings 
including in combination with docetaxel and cisplatin 
in HNSCC (NCT02508246),22 with radiotherapy in child-
hood pontine glioma (NCT01922076), with temozolo-
mide and radiotherapy in glioblastoma (NCT01849146), 
and with cisplatin and radiotherapy in cervical cancer 
(NCT01958658).
In summary, the available mechanistic data lend strong 
support to combining AZD1775 with cisplatin and with 
POCRT in the clinic. Given that the predictive effect of 
TP53 mutation on such combinations has yet to be clin-
ically validated, this study does not prospectively stratify 
patients based on any such clinical or biological char-
acteristic. Biomarker data generated, however, will be 
important in understanding the mechanism of action 
and informing future combination studies.
Incorporating AZd1775 into clinical management
A recent randomised phase III study of neoadjuvant 
chemotherapy in a Chinese population with locally 
advanced resectable oral cavity cancer showed that 
docetaxel, cisplatin and 5- fluorouracil (TPF) treatment 
generated a response rate of 80%, with an exploratory 
analysis showing that clinical responders had improved 
overall survival and local control.23 There was no 
improvement in overall survival for the study group as a 
whole compared with the control group without upfront 
TPF chemotherapy, possibly because patients who 
would ordinarily have received POCRT received PORT 
alone in this study. In an earlier study, TP53 mutation 
conferred increased resistance to preoperative cisplatin- 
based chemotherapy in oral cancer.24 While neoadjuvant 
chemotherapy has yet to find a definitive role prior to 
surgery, these findings raise the possibility that chemo-
sensitisation may further improve outcomes.
The preoperative group A sets out to test this hypoth-
esis by combining 1 week of AZD1775 alone, with a 
second week of cisplatin (40 mg/m2) with AZD1775. 
This short course of treatment will minimise any delay 
between diagnosis and definitive surgery and prevent 
unacceptable delay for the non- responders from getting 
standard treatment. If this is a promising combination, 
the long- term aim is to test AZD1775 in the neoadjuvant 
setting to downstage the disease through treatment with 
cisplatin and AZD1775 in the preoperative setting, which 
may decrease the extent of surgery, and may also reduce 
the need for PORT/POCRT by reducing the involved 
margin rate. Many patients with tumours that have high- 
risk histopathological features develop relapsed disease 
within the anatomical area treated to a high radiation 
dose. Chemosensitisation and radiosensitisation via 
inhibition of the G2/M checkpoint by AZD1775 has the 
potential to improve outcomes with acceptable toxicity. 
This possibility is the basis of the treatment delivered in 
the group B cohort.
METhodS
Wisteria trial objectives
Primary objectives are to determine the recommended 
dose and safety profile of AZD1775 with cisplatin in the 
group A preoperative (window- of- opportunity) setting, 
and with cisplatin/radiotherapy in the group B post-
operative setting. Other objectives: obtain information 
regarding group A and B disease- free survivals; evaluate 
AZD1775 pharmacodynamic (PD) effects when admin-
istered with cisplatin (group A); identify and correlate 
potential predictive biomarkers with PD markers of DNA 
damage (group A); determine the rate of R0, R1 or R2 
resection status and surgical complication (group A); and 
group B quality of life (QoL).
Trial design
Wisteria is an open- label, dose- finding, multicentre phase 
I trial to determine the highest safest dose of AZD1775 in 
combination with a single dose of cisplatin in the preop-
erative setting as a window of opportunity trial (group A); 
and to determine the maximum tolerated dose (MTD) of 
AZD1775 in combination with cisplatin/radiotherapy in 
the postoperative setting (group B): both groups recruit 
and run in parallel (figure 1). The dose- escalation design 
is based on the modified time- to- event continual reassess-
ment method (TITE- CRM),25–28 requiring a maximum of 
21 patients per group, and encompassing up to four dose 
levels of AZD1775.
The MTDs of AZD1775 for both groups are expected 
to differ given the additional toxicities of radiotherapy 
in group B. The dose- limiting toxicity (DLT) monitoring 
periods are defined in table 1. Conservative target DLT 
rates are selected to minimise the likelihood of compro-
mising individual patient’s radical surgery and/or PORT. 
To maximise recruitment, reduce trial suspension time 
between cohorts, while balancing safety and optimal 
patient allocation, screening cohorts of up to five patients 
will be allowed if the dose has previously been tested. 
Recruited patients will be allocated to the current recom-
mended dose up to a maximum of five. Patients who 
become unevaluable may be replaced.
The model will be updated after every two to three 
evaluable patients, with any subsequent eligible patients 
(not already receiving treatment) allocated to the latest 
recommended dose cohort. Subsequent cohorts will be 
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Figure 1 Wisteria trial schema. Group A patients were required to have received a minimum treatment of chemotherapy 
(cisplatin) and AZD1175 in combination to be DLT evaluable. Group B patients were required to have received a minimum 
of 2 weeks of treatment (half the total scheduled AZD1775 dose) to be DLT evaluable. DLT, dose- limiting toxicity; PD, 
pharmacodynamic; TITE- CRM, time- to- event continual reassessment method.
assigned a dose level using all the data observed until 
either—the MTD is determined, the maximum sample 
size is reached, or the trial is stopped early due to unac-
ceptable DLT levels at the lowest dose.
Patient population, screening and consent
Group A patients are those with biopsy- proven squa-
mous cell carcinoma of the oral cavity, larynx or hypo-
pharynx (having accessible tumours for rebiopsy under 
local anaesthetic or via ultrasound- guided biopsy), and 
due to undergo surgery. Patients in group B consist of 
those already diagnosed with oral cavity, larynx or hypo-
pharynx squamous cell carcinoma, who have undergone 
surgery and are considered at risk of relapse after surgery 
(ie, with positive margins and/or nodal extracapsular 
spread). Patients with cancer of the oropharynx will not 
be included. Since Human papillomavirus (HPV) is only 
routinely tested in oropharyngeal squamous cell carci-
noma or unknown primary of squamous cell carcinoma 
in the National Health Service (NHS), HPV status was 
not determined or requested for the tumours as part of 
the study. Patients who meet the criteria will be supplied 
with the patient information sheet. If informed consent 
(online supplementary appendices 1 and 2) is given, the 
patient undergoes a full screening evaluation to ensure 
they satisfy the eligibility criteria prior to registration 
(boxes 1 and 2).
dose selection
Based on AstraZeneca studies,29 30 the Wisteria trial uses 
3- day dosing, giving AZD1775 weekly to coincide with 
cisplatin administration thereby potentiating the DNA 
damage effects. The maximum total dose of AZD1775 
1800 mg in combination with 1 dose of 40 mg/m2 
cisplatin for group A is substantially lower than AZD1775 
monotherapy dose 2250 mg every 21 days (225 mg two 
times per day orally over 2.5 days per week for 2 weeks per 
21 day cycle) used in Do et al; and although in combina-
tion with cisplatin, the highest dose level (dose level 2) is 
likely to be safe.
A similar dose escalation algorithm will be carried out 
in group B with a higher acceptable target DLT level of 
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Table 1 Details of the Wisteria TITE- CRM trial design for groups A and B
Group A Group B
Maximum no of Patients Up to 21 patients in each group
MTD definition Dose closest to where 25% patients 
experience a DLT
Dose closest to where 30% patients 
experience a DLT
Minimum treatment to be DLT 
evaluable
Patients to have received the minimum of 
AZD1775 and cisplatin doses scheduled up 
to and including day 8
Patients to have received a minimum of the 
first 2 weeks of treatment as scheduled
DLT reporting period Minimum of 30 days from start of treatment 
up to 42 days for delays in surgery due to 
treatment related toxicity (if this exceeds 42 
days then this delay will be classified as a 
DLT).
Minimum of 56 days (8 weeks) from start 
of radiotherapy, and up to 84 days (12 
weeks), that is, up to 6 weeks from end of 
postoperative chemoradiation therapy.
Dose levels
Cisplatin 
(intravenous) over 
1 hour
(day 8)
AZD1775 PO two 
times per day 3 
days
(days 1–3, 8–10)
Cisplatin 
(intravenous) 
over 1 hour
(day 2 weeks 
1–5)
Radiotherapy
(5 days per week 
over 6 weeks)
AZD1775 PO two 
times per day 3 
days
(days 2–4 weeks 1, 
2, 4 and 5)
-1 40 mg/m2 75 mg 40 mg/m2 54–65 Gy in 30# 50 mg
0 (starting dose level) 100 mg 75 mg
1 125 mg 100 mg
2 150 mg 125 mg
DLT, dose- limiting toxicity; MDT, multidisciplinary team; TITE- CRM, time- to- event continual reassessment method.
30% allowing for multiple dosing of cisplatin with radio-
therapy in combination with AZD1775.31–33 Trial doses 
and schedule are set out in table 1. AZD1775 is adminis-
tered orally. The feasibility of the oral administration will 
be evaluated in postoperative patients.
Trial treatments
Group A (preoperative)
Patients will receive specified dose of AZD1775 by mouth 
(PO) two times per day at 12 hours intervals (2 hours 
before or after food) for 3 days, commencing on days 
1 and 8, with 40 mg/m2 intravenous cisplatin delivered 
over 1 hour on day 8. A missed dose of more than 6 hours 
should be skipped. If vomiting occurs, patient should 
not retake the dose but wait until next scheduled dose. 
Surgery is not to exceed 42 days from start of neoadjuvant 
chemotherapy.
Group B (postoperative)
Patients will receive specified dose of AZD1775 PO two 
times per day for 3 days, commencing on days 2, 9, 23 and 
30, and 40 mg/m2 intravenous cisplatin delivered over 1 
hour on days 2, 9, 16, 23 and 30 (days are timed from 
the start of radiotherapy delivery). Radiotherapy (65 Gy 
and 54 Gy in 30 fractions given for 5 days per week over 
6 weeks: D1-5, D8-12, D15-19, D22-26, D29-33, D36-40, 
to high- risk and low- risk volumes, respectively, as per 
Wisteria Radiotherapy Guidelines, see online supplemen-
tary appendices 3–6) will commence within 3 months of 
surgery and given concurrently with chemotherapy.
For both groups A and B, cisplatin dose banding is not 
permitted. BSA to be calculated according to local prac-
tice; if weight changes>10% then cisplatin dose should be 
recalculated.
AZD1775 (morning dose) should be administered 
prior to cisplatin, and group B to receive cisplatin 1 hour 
before radiotherapy; standard supportive treatment, 
including premedication with antiemetics (excluding 
aprepitant and fosaprepitant), is allowed according to 
standard practice guidelines.
Trial outcome measures
Primary outcome measures
The recommended doses of AZD1775 (determined by 
the modified TITE- CRM) for group A and B.
 ► Group A: the highest safe dose in combination with 
cisplatin with a predefined target DLT probability of 
25% for up to 42 days from start of treatment.
 ► Group B: the MTD in combination with cisplatin/
radiotherapy with a target DLT of 30% for up to 12 
weeks from the start of treatment.
 ► Safety profile of AZD1775 in both group A and B.
Secondary outcome measure
Disease- free survival time for both groups and recorded 
from commencement of treatment to the date of disease 
recurrence, patient death or end of trial follow- up period.
Tertiary research outcome measures
PD effects of AZD1775 and correlation with TP53 muta-
tion status; pharmacokinetic (PK) effects of AZD1775 will 
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box 1 Inclusion criteria—all patients
 ► Histologically confirmed diagnosis of oral, laryngeal or hypopharyn-
geal squamous cell carcinoma.
 ► Multidisciplinary team (MDT) recommendation for surgical resection 
with curative intent.
 ► Eastern Cooperative Oncology Group performance status 0/131.
 ► Age≥18 to≤70 years.
 ► Creatinine clearance, measured by glomerular filtration rate 
(GFR),≥60 mL/min at baseline calculated using local practice calcu-
lation. If this is ≤60 mL/min then an isotopic GFR may be carried out 
and must be >60 mL/min.
 ► Acceptable cardiac function. If significant cardiac history, then re-
quired for patient to have left ventricular ejection fraction ≥55% by 
echocardiogram (ECHO) or multiple gated acquisition scan (if ECHO 
is equivocal).
 ► Normal liver and bone marrow function:
 – Haemoglobin ≥100 g/L.
 – Absolute neutrophil count ≥1.5×109/L.
 – Absolute platelet count ≥100×109/L.
 – Aspartate transaminase or alanine aminotransferase ≤2.5 upper 
limit of normal (ULN).
 – Total bilirubin ≤1.5 ULN (except for patients with known Gilbert’s 
syndrome).
 ► Male and female participants must agree to take appropriate mea-
sures to prevent pregnancy. Contraceptive measures should be used 
for 2 weeks prior to trial entry, during the trial and for at least 6 
months after last receiving treatment. Acceptable methods of con-
traception include total abstinence (if this is the patient’s usual and 
preferred lifestyle choice), tubal ligation, combined oral, transder-
mal or intravaginal hormonal contraceptives, medroxyprogesterone 
injections (eg, Depo- Provera), copper- banded intrauterine devices; 
hormone impregnated intrauterine systems and vasectomised part-
ners. All methods of contraception (with the exception of total absti-
nence) should be used in combination with the use of a condom by 
their male sexual partner for intercourse.
In addition to general criteria
 ► Group A—Accessible tumours for rebiopsy to be taken under local 
anaesthetic or via ultrasound- guided biopsy.
 ► Group B—High- risk histopathological features after surgical resec-
tion, that is, nodal extra- capsular spread and/or tissue resection 
margin <1 mm as agreed at MDT.
 ► Group B—Patients who have previously registered to group A can 
be considered for inclusion in group B.
box 2 Exclusion criteria—all patients
 ► Any previous treatment for the same cancer, or previous head and 
neck malignancy, apart from laser excision of carcinoma in situ, with 
minimal residual functional deficit or registration and treatment in 
group A prior to surgery.
 ► Patients with cancer of the oropharynx or non- primary cancer will 
not be included.
 ► Any metastatic disease from any primary site.
 ► Use of an investigational medicinal product concurrently or within 4 
weeks of starting this trial.
 ► Uncontrolled intercurrent illness, which will interfere with patient’s 
trial participation, for example,
 – Myocardial infarction within 6 months.
 – Congestive cardiac failure.
 – Unstable angina.
 – Symptomatic cardiomyopathy.
 – Chronic infections.
 – Active peptic ulcer or liver disease.
 – Serious psychiatric condition limiting ability to comply with trial 
protocol.
 ► Clinical evidence of current heart failure (≥New York Heart 
Association Class II32).
 ► Clinical evidence of atrial fibrillation (heart rate >100 bpm, within 6 
months prior to trial entry).
 ► Unstable ischaemic heart disease (myocardial Infarction within 6 
months prior to trial entry or angina requiring the use of nitrates 
greater than once weekly).
 ► Patients who have a history of torsades de pointes (unless all risk 
factors that contributed to torsades have been corrected).
 ► Active gastrointestinal disease that might limit absorption of study 
drug, for example, coeliac disease, Crohn’s disease, ulcerative coli-
tis, pancreatic insufficiency.
 ► Evidence of any psychological, familial, sociological or geographical 
condition potentially hampering protocol compliance
 ► Participation in another interventional clinical trial while taking part 
in this trial.
 ► Patients who are unable to discontinue any prohibited drug, includ-
ing live vaccines and unable to tolerate a washout period for at least 
14 days prior to trial entry (including: CYP3A4 inhibitors; CYP3A4 in-
ducers; CYP3A, CYP3A4, CYP2C19, CYP1A2 sensitive substrates or 
substrates with narrow therapeutic range; P- gp substrates, strong 
P- gp inhibitors and BCRP substrates33).
 ► Patients with any contraindications to cisplatin use.
 ► Clinical judgement by the investigator that the patient should not 
participate in the study.
 ► Known hypersensitivity to the study drugs or active substances or 
excipients of the preparations.
 ► Pregnant or breastfeeding patients.
 ► Significant pre- existing neuropathy which currently interferes with 
the patient’s daily life.
 ► Mean resting corrected QTc interval using the Fridericia’s formula34 
>450 ms (male) and >470 ms (female) (as calculated per institu-
tional standards) obtained from three ECGs 2–5 min apart at study 
entry, or congenital long QT syndrome.
 ► Inability to swallow oral medications.
be determined; optimise, validate and test feasibility of 
assays to investigate serum, ctDNA and RNA biomarkers; 
investigate the feasibility of immune function testing in a 
multicentre setting; complete pathological response rate 
for group A; positive resection margin status in group A; 
surgical complication in group A; and QoL in group B 
using European Organization for Research and Treat-
ment of Cancer (EORTC) C30 (V.3.0),34 EORTC QLQ- 
H&N3535 and M.D. Anderson Dysphagia Inventory,36 as 
summarised in table 2.
Assessment data will be collected as listed in online 
supplementary appendix tables 7 and 8.
dLT and dose management
Predefined DLTs have been specified by the Clinical 
Investigators (box 3), and recorded toxicity profiles 
for the Wisteria treatments are given in online supple-
mentary appendix table 9. Toxicity is assessed using the 
National Cancer Institute Common Terminology Criteria 
for Adverse Events V.4.037 unless otherwise specified. Any 
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Table 2 Trial summaries of group A and group B
Summary of group A
  Setting Patients undergoing surgical resection
  Design Modified TITE- CRM
  Chemotherapy Cisplatin 40 mg/m2 intravenous over 1 hour on day 8
  AZD1775 AZD1775 PO BID for 3 days on days 1–3 and 8–10 dose- recommendation according to the modified 
TITE- CRM model
  Surgery Resection within 42 days of start of neoadjuvant treatment
  DLT reporting period The minimal reporting period is 30 days from start of treatment, but patients will be monitored up to 
42 days for delay in surgery due to treatment- related toxicity
  PK samples Pharmacokinetic samples will be collected pre and post—the fifth dose of AZD1775 on days 3 and 
10 (4 samples per patient)
  PD markers Assess CDK1, pCDK1, γH2AX, p53, p16, HH3, pHH3, Ki67, C3, CC3, p21, WEE1, pWEE1, PDL-1 
and TILS, and other markers of particular interest
  Follow- up Clinically for at least 12 weeks from start of treatment
Summary of group B
  Setting Postoperative patients with high- risk disease (involved resection margins +/or extracapsular nodal 
spread) receiving chemoradiation
  Design Modified TITE- CRM
  Chemotherapy Cisplatin 40 mg/m2 intravenous over 1 hour on day 2 of weeks 1–5 of radiotherapy
  Radiotherapy External beam radiation therapy (30 fractions over 6 weeks) to start within 3 months of surgery. Dose 
levels are 65 Gy for positive margin, 60 Gy to lymph node levels that have been dissected and 54 Gy 
to elective lymph node areas. A dose of 65 Gy may also be applied to areas of gross extracapsular 
spread at the discretion of the treating clinician.
  AZD1775 AZD1775 PO BID for 3 days on days 2–4 of weeks 1, 2, 4 and 5 (no treatment with AZD1775 during 
weeks 3 and 6). Dose recommendation will be according to modified TITE- CRM model.
  DLT reporting period The minimal reporting period is 56 days (8 weeks) from start of radiotherapy, but patients will be 
monitored for DLTs up to 84 days (12 weeks), that is, up to 6 weeks from the end of POCRT
  PK samples Pharmacokinetic samples will be collected pre and post—the fifth dose of AZD1775 on week 1—day 
4 (2 samples per patient)
DLT, dose- limiting toxicity; PD, pharmacodynamic; PK, pharmacokinetic; POCRT, postoperative chemoradiation; TITE- CRM, time- to- event 
continual reassessment method.
patient requiring a toxicity- related dose delay of more than 
21 days must be discontinued from the study unless there 
is approval from the chief investigator for the patient to 
continue. For group A, if any treatment- related grade≥3 
toxicity develops in week 1, cisplatin and AZD1775 are 
discontinued in week 2. For group B, if calculated GFR 
falls below 60 mL/min, immediately before any cycle of 
concomitant chemotherapy, weekly cisplatin should be 
discontinued and consideration given to substitute with 
weekly carboplatin (Area Under the Curve (AUC)=1.5), 
according to routine local practice.
In both groups, a full blood count is obtained at the 
beginning of each week. If haematological toxicity occurs, 
treatment should be modified as per online supplemen-
tary appendix tables 10 and 11. For non- haematological 
toxicities, treatment should also be modified as per online 
supplementary appendix tables 12–16.
The selection of PD markers to test are different for 
group A and group B as group A enables examination of 
samples pretreatment and post- treatment with AZD1775.
Concomitant medications
All concomitant medications received within 14 days 
before the first dose of study medication and for 12 weeks 
after the last dose of study medication should be recorded. 
Medications may be administered for maintenance of 
existing conditions prior to study enrolment or for a new 
condition that develops while on study. The treatments 
and medications listed in online supplementary appendix 
17 are prohibited or to be used with caution while in this 
study. No other investigational therapy or anticancer 
agents, other than the study medications, should be given 
to patients. If such agents are required for a patient, then 
the patient must first be withdrawn from the study. Live 
vaccines are not permitted.
discontinuation of investigational medicinal product
Patients should discontinue trial treatment in the 
following circumstances: intolerable toxicity; confirmed 
disease recurrence; pregnancy; severe non- compliance to 
protocol; development of any study- specific criteria for 
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box 3 dose- limiting toxicities (dLT)
Patients experiencing any of the following adverse reactions (ARs) 
during the reporting period will be considered to have experienced a 
DLT:
 ► Grade 3 or 4 neutropenia lasting for >7 days despite adequate 
granulocyte- colony stimulating factor (G- CSF) support.
 ► Grade 4 febrile neutropenia, which includes grade 3 febrile neutro-
penia accompanied by systemic inflammatory response syndrome/
sepsis or other life- threatening consequences.
 ► A third occurrence of grade 2 or worse neutropenia despite G- CSF 
support.
 ► Grade 3 or 4 thrombocytopenia lasting ≥7 days.
 ► Any occurrence of grade 4 anaemia.
 ► Any occurrence of grade 4 mucositis.
 ► Any occurrence of grade 3 nausea despite preventative and sup-
portive care according to local practice. Tube feeding is not consid-
ered a DLT.
 ► Any occurrence of grade 4 vomiting despite preventative and sup-
portive care according to local practice. Tube feeding is not consid-
ered a DLT.
 ► Any occurrence of grade 4 diarrhoea despite preventative and sup-
portive care according to local practice.
 ► Any AR which results in an omission of chemotherapy administra-
tion and/or study treatment for >14 days.
 ► A start- of- treatment- to- surgery time of >42 days in group A as a 
result of a treatment- related toxicity.
 ► Grade 3 mucositis lasting >42 days after the end of treatment in 
group B.
 ► An overall treatment time of >49 days from the first day of radio-
therapy in group B as a result of a treatment- related toxicity.
 ► Any grade 3 or 4 non- haematological AR (except for fatigue, nausea, 
vomiting and diarrhoea) for which medical intervention that lasts 
>7 days is required and the investigators deem that this AR is more 
severe or prolonged than what would be expected of standard treat-
ment. Tube feeding is not considered a DLT.
 ► Any clinically significant occurrence which investigators within the 
trial management group agree would place the patient at undue 
safety risk
If the inability to swallow the AZD1775 capsule develops during the 
course of trial treatment, this event should be noted in the relevant sec-
tion on the Suspected DLT form and reported immediately. However, this 
is not considered a DLT in itself.
box 4 Adverse event and serious adverse event 
definitions
Adverse event
Any untoward medical occurrence in a patient or clinical trial subject 
administered a medicinal product and which does not necessarily have 
a causal relationship with this treatment.
Serious adverse event
Any untoward medical occurrence or effect that at any dose may:
 ► Result in death.
 ► Is life threatening.
 ► Requires hospitalisation or prolongation of existing in- patient 
hospitalisation.
 ► Results in persistent or significant disability or incapacity.
 ► Is a congenital anomaly/birth defect.
 ► Is considered medically significant by the clinical investigator.
discontinuation and investigator decision, for example, if 
the patient requires a prohibited concomitant medication.
Safety monitoring: adverse events and serious adverse events
All medical occurrences which meet the definition of 
an adverse event (AE) or serious AE (SAE) (as defined 
in box 4) should be reported. This includes abnormal 
laboratory findings of grade 3 and above only. AEs will 
be monitored for and reported from date of informed 
consent until the 12- week follow- up visit for group A and 
until the 12- month follow- up visit for group B. Investiga-
tors should report SAEs within 24 hours of first knowledge 
of the event, until 12- week follow- up visit. After this time, 
expedited reporting is no longer required and should 
be reported as an AE. Any poststudy serious unexpected 
serious adverse reactions (SUSARs) should be reported 
within 24 hours. An independent Safety Committee will 
review all SAEs. Fatal or life- threatening SUSARs will be 
reported to the Medicines and Healthcare products Regu-
latory Agency (MHRA) and Research Ethics Committee 
(REC) within 7 days. Detailed follow- up information will 
be provided within an additional 8 days. All other events 
categorised as SUSARs will be reported within 15 days. 
The MHRA and REC will be notified immediately if a 
significant safety issue is identified during the course of 
the trial. All SAEs relating to AZD1775 will be reported to 
AstraZeneca within 24 hours of notification.
data collection and monitoring
Data will be collected via a set of forms capturing details 
of eligibility, baseline characteristics, treatment and 
outcome details. This trial will use an electronic remote 
data capture system. SAE reporting and notification of 
pregnancy will be paper based. All missing and ambig-
uous data will be queried. In all cases, it remains the 
responsibility of the investigator to ensure that data are 
accurate. Details regarding data collection for group A 
and B are given in online supplementary appendix tables 
7 and 8. The Investigator will permit trial- related moni-
toring, audits, ethical review and regulatory inspection(s) 
at their site, providing direct access to source data/
documents.
Statistical methodology
The AZD1775 dose is allocated to patients according to 
a modified Bayesian TITE- CRM, using an empiric dose- 
toxicity model, F(x,β) given as:
 F
(
x,β
)
= xexp
(
β
)
for 0 < x < 1 
where model parameter β is assumed random and 
follows a normal distribution and will be estimated by its 
posterior mean.27 At the point of model update, patients 
who have started treatment but have not experienced 
DLT (and have completed their full DLT assessment) 
will be included in the probability calculation with a 
weight equal to the proportion of the full DLT assessment 
period they have completed. Patients who experience 
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DLT within the assessment period or complete the full 
assessment period are assigned full weight. The model 
also enables inclusion of partial patient information that 
cannot be formally evaluated for DLTs due to withdrawal, 
treatment discontinuation or death, which are unrelated 
to treatment, within the DLT assessment period.
Table 1 displays the four dose levels of AZD1775 for 
group A and group B. For both groups, dosing starts at 
level 0 and allows for possible escalation to two higher 
levels, or deescalation to a lower dose, as recommended 
by the TITE- CRM, without skipping untried doses in esca-
lation. The TITE- CRM model aims to recommend the 
next dose with estimated DLT probability closest to the 
target DLT level, taking into account the practical consid-
erations as detailed below:
Practical considerations
 ► Restriction is applied to avoid skipping of untried 
doses in escalation.
 ► Stop early due to safety concerns if there is sufficient 
evidence that the posterior probability of DLT at 
the lowest dose is greater than the target DLT rate, 
implying that the lowest dose is too toxic.
 ► Stop early if sufficient patients have been allocated 
to the current MTD (and remains the recommended 
dose level for the next cohort if the trial continues) 
before the full recruitment of 21 patients.
 ► The minimum DLT period is set at 30 days for group A 
and 8 weeks for group B. This means that partial infor-
mation of no DLT in a patient can only be included in 
the model if they have been followed up for at least 30 
days or 8 weeks in group A and B, respectively. (The 
full DLT assessment periods are 42 days and 12 weeks 
in group A and B, respectively.) This feature can easily 
be accommodated using the TITE- CRM model.
 ► A ‘look ahead’ strategy will be implemented if the next 
recommended dose level by the modified TITE- CRM 
model will not be influenced by the outcome of the 
remaining patient(s) of a particular cohort (DLT or 
no DLT). By implementing this strategy, the next 
cohort can be recruited immediately without awaiting 
the final observations from the current cohort, thus 
reducing waiting time between cohorts.
Analysis of outcome measures
The primary outcome measures are the recommended 
doses of AZD1775 in group A and group B, and the safety 
profile of the combination therapy. To be DLT evalu-
able, group A patients must have received AZD1775 and 
cisplatin doses scheduled up to and including day 8; group 
B patients must have received at least the first 2 weeks 
of treatment. The recommended doses of AZD1775 will 
be those that have an estimated DLT rate closest to the 
target DLT rate: 25% for group A; 30% for group B. DLT 
rates and corresponding 90% probability intervals will 
be reported. Safety will be monitored in patients treated 
with at least one dose of the trial treatment until end of 
follow- up. All adverse reactions, AEs, SAEs, suspected 
unexpected SUSARs, deaths, deviations and withdrawals 
experienced by trial patients, throughout the trial’s dura-
tion, will be reported separately for group A and group B.
Disease- free survival in group A and group B patients will 
be reported separately. Patients will be followed up for 12 
months after which, time- to- event outcomes will be assessed 
using the method of Kaplan and Meier. Median disease- free 
survival with corresponding 95% CIs will be reported where 
appropriate. Further analysis will be performed separately 
on subsets of group A and B patients who have completed 
at least 90% of AZD1775 trial scheduled treatments.
Tertiary outcome measures will be explored and 
reported descriptively using basic descriptive statistics 
where appropriate:
 ► PD effects of AZD1775 and correlation with TP53 
mutation status: Expression levels of parameter-
schanges over time and correlation with TP53 muta-
tion status will be reported.
 ► PK effects of AZD1775: Blood samples for PK anal-
yses are collected (as scheduled in online supplemen-
tary appendix tables 7 and 8). Circulatory levels of 
AZD1775 and changes over time will be reported.
 ► Complete pathological response rate for group A: 
Pathology data will be reported along with the results 
of the formalin- fixed paraffin- embedded (FFPE) 
tissue samples. Response rate will be reported as the 
number of evaluable group A patients showing a 
response (numerator) divided by the total number of 
group A evaluable patients (denominator).
 ► Positive resection margin status in group A: This will 
be reported as the number and percentage of group A 
patients showing positive resection margins.
 ► Surgical complications in group A: This will be 
reported by category of surgical complication with 
severity and given as numbers and percentages.
 ► QoL in group B: QoL data are gathered over time and 
will be reported as changes over time and plotted. 
In addition to the descriptive analyses, the repeated 
measures over time data may be modelled, if appro-
priate, with a linear mixed effects model (taking 
subject correlation into account) using linear or more 
flexible models.
Interim analyses will be performed once each cohort 
of patients has been recruited and assessed within the 
defined assessment timeframe of DLTs. In each meeting, 
the safety committee will be presented with recruitment 
and safety data, together with a statistical report for next 
dose recommendation. Additional meetings might be 
convened if late- onset DLTs were observed. The safety 
committee will decide whether to progress to the recom-
mended dose as indicated by the modified TITE- CRM 
model. The final analyses will be conducted in two parts: 
(1) analyses of the primary outcome measures of MTDs 
for groups A and B, to be carried out approximately 
3 months after the safety review of the last cohort in 
each group and (2) longer- term outcomes—including 
secondary and tertiary outcome measures and updated 
safety data, to be carried out 1 year after the end of trial.
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TRIAL oRgAnISATIon And STRuCTuRE
The trial is sponsored by the University of Birmingham, 
UK and conducted under the auspices of the Cancer 
Research UK Clinical Trials Unit, University of 
Birmingham, UK according to their local procedures.
The trial management group (TMG) will include as a 
minimum: chief investigator, coinvestigators, lead and 
trial statisticians, trial management team leader and trial 
coordinator (other appropriate key personnel will be 
invited to attend meetings as required). This group will 
be responsible for legal obligations, day- to- day running 
and management of the trial.
The safety committee provides support on decisions 
surrounding the review of DLT information and dose- 
changing decisions. Membership of this group includes 
the TMG, independent members and selected principal 
investigators.
EThICS And dISSEMInATIon
The trial will be performed in accordance with the 18th 
World Medical Association General Assembly, Helsinki, 
Finland, June 1964, amended at the 48th World Medical 
Association General Assembly, Somerset West, Republic 
of South Africa, October 1996 (website: http://www. 
wma. net/ en/ 30publications/ 10policies/ b3/ index. 
html); conducted in accordance with the Research 
Governance Framework for Health and Social Care, the 
applicable UK Statutory Instruments, (which include 
the Medicines for Human Use Clinical Trials 2004 and 
subsequent amendments, The Human Tissue Act 2008) 
and Good Clinical Practice E6(R2); and carried out 
under a Clinical Trial Authorisation in accordance with 
the Medicines for Human Use Clinical Trials regula-
tions. The protocol and subsequent amendments will be 
submitted to and approved by REC prior to circulation. 
Personal data recorded on all documents will be regarded 
as strictly confidential and will be handled and stored in 
accordance with the General Data Protection Regulation 
2016/679 and the Data Protection Act (2018).
Trial findings will be published in a peer- reviewed 
journal and disseminated at appropriate conferences, 
departmental and scientific meetings.
Author affiliations
1Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, 
UK
2University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
3Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, 
University of Birmingham, Birmingham, UK
4SIMBEC Research Limited, Merthyr Tydfil, UK
5University College London, London, UK
6Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK
7Institute of Cancer Research, London, UK
8Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, UK
9Leeds Teaching Hospitals NHS Trust, Leeds, UK
10Institute of Immunology and Immunotherapy, University of Birmingham, 
Birmingham, UK
Twitter James Good @drjamesgood, Joanna Parish @HPVSupergroup and Christina 
Yap @ChristinaBYap
Acknowledgements Wisteria was supported by Experimental Cancer Medicine 
Centres (ECMC) funding and by the ECMC Network.
Contributors The study was conceived by HM and JG; designed by HM, JG, AKo 
and CY; and the protocol written by HM, AKo, JG, CY, LL, RM, AKi, RS, JSav, JSac, 
MF, JP, SS, PM, GM and KH. AKi, AKo, JG, JSav and CY wrote the manuscript with 
input from all authors.
Funding Cancer Research UK (code C19677/A20959) and AstraZeneca through the 
CRUK’s Combinations Alliance and Experimental Cancer Medicine Centre (ECMC). 
AstraZeneca provides AZD1775 to participating sites free- of- charge, and was 
consulted over the trial design but are not involved in the trial management group 
or safety committee. The Combinations Alliance, a Cancer Research UK model, 
aims to drive academic- industrial partnership, generating novel treatment options 
that would otherwise unlikely be realised. Novel combination ideas are generated 
and delivered via the UK’s Experimental Cancer Medicine Centre (ECMC) network 
of clinical and scientific experts working together to accelerate innovation in early- 
phase oncology research for patient benefit.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
oRCId ids
Joshua Savage http:// orcid. org/ 0000- 0003- 0599- 0245
Christina Yap http:// orcid. org/ 0000- 0002- 6715- 2514
Hisham Mehanna http:// orcid. org/ 0000- 0002- 5544- 6224
REFEREnCES
 1 Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer 
J Clin 2009;59:225–49.
 2 Haddad RI, Shin DM. Recent advances in head and neck cancer. N 
Engl J Med 2008;359:1143–54.
 3 Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation 
with or without concomitant chemotherapy for locally advanced head 
and neck cancer. N Engl J Med 2004;350:1945–52.
 4 Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. 
Sem Rad Onc 2015;25:11–17.
 5 Kang H, Kiess A, Chung CH. Emerging biomarkers in head and neck 
cancer in the era of genomics. Nat Rev Clin Oncol 2015;12:11–26.
 6 Olivier M, Hollstein M, Hainaut P. Tp53 mutations in human cancers: 
origins, consequences, and clinical use. Cold Spring Harb Perspect 
Biol 2010;2:a001008.
 7 Petitjean A, Achatz MIW, Borresen- Dale AL, et al. Tp53 mutations in 
human cancers: functional selection and impact on cancer prognosis 
and outcomes. Oncogene 2007;26:2157–65.
 8 Dillon MT, Good JS, Harrington KJ. Selective targeting of the 
G2/M cell cycle checkpoint to improve the therapeutic index of 
radiotherapy. Clin Oncol 2014;26:257–85.
 9 Hirai H, Iwasawa Y, Okada M, et al. Small- Molecule inhibition of 
Wee1 kinase by MK-1775 selectively sensitizes p53- deficient tumour 
cells to DNA- damaging agents. Mol Can Ther 2009;8:2992–3000.
 10 Van Linden AA, Baturin D, Ford JB, et al. Inhibition of Wee1 
sensitizes cancer cells to antimetabolite chemotherapeutics in vitro 
and in vivo, independent of p53 functionality. Mol Cancer Ther 
2013;12:2675–84.
 11 Magnussen GI, Holm R, Emilsen E, et al. High expression of Wee1 is 
associated with poor disease- free survival in malignant melanoma: 
potential for targeted therapy. BMJ Cancer 2013;13:288.
 12 Mir SE, De Witt Hamer PC, Krawczyk PM, et al. In silico analysis of 
kinase expression identifies Wee1 as a gatekeeper against mitotic 
catastrophe in glioblastoma. Cancer Cell 2010;18:244–57.
 13 Wu Z, Doondeea JB, Gholami AM, et al. Quantitative chemical 
proteomics reveals new potential drug targets in head and neck 
cancer. Mol Cell Proteomics 2011;10:M111:M111.011635.
 14 Hirai H, Iwasawa Y, Okada M, et al. Small- Molecule inhibition of 
Wee1 kinase by MK-1775 selectively sensitizes p53- deficient tumor 
cells to DNA- damaging agents. Mol Cancer Ther 2009;8:2992–3000.
copyright.
 o
n
 M
arch 18, 2020 at University of G
lasgow. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-033009 on 16 March 2020. Downloaded from 
11Kong A, et al. BMJ Open 2020;10:e033009. doi:10.1136/bmjopen-2019-033009
Open access
 15 Bridges KA, Hirai H, Buser CA, et al. MK-1775, a novel Wee1 kinase 
inhibitor, radiosensitizes p53- defective human tumor cells. Clin 
Cancer Res 2011;17:5638–48.
 16 Do K, Doroshow JH, Kummar S. Wee1 kinase as a target for cancer 
therapy. Cell Cycle 2013;12:3159–64.
 17 Osman AA, Monroe MM, Ortega Alves MV, et al. Wee-1 kinase 
inhibition overcomes cisplatin resistance associated with high- risk 
TP53 mutations in head and neck cancer through mitotic arrest 
followed by senescence. Mol Cancer Ther 2015;14:608–19.
 18 Caretti V, Hiddingh L, Lagerweij T, et al. Wee1 kinase inhibition 
enhances the radiation response of diffuse intrinsic pontine gliomas. 
Mol Cancer Ther 2013;12:141–50.
 19 Sarcar B, Kahali S, Prabhu AH, et al. Targeting radiation- induced 
G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in 
glioblastoma cell lines. Mol Cancer Ther 2011;12:2405–14.
 20 Karnak D, Engelke CG, Parsels LA, et al. Combined inhibition of 
Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Clin 
Cancer Res 2014;20:5085–96.
 21 Guertin AD, Li J, Liu Y, et al. Preclinical evaluation of the Wee1 
inhibitor MK-1775 as single- agent anticancer therapy. Mol Cancer 
Ther 2013;12:1442–52.
 22 Méndez E, Rodriguez CP, Kao MC, et al. A phase I clinical trial of 
AZD1775 in combination with neoadjuvant Weekly docetaxel and 
cisplatin before definitive therapy in head and neck squamous cell 
carcinoma. Clin Cancer Res 2018;24:2740–8.
 23 Zhong L, Zhang C, Ren G, et al. Randomized phase III trial of 
induction chemotherapy with docetaxel, cisplatin, and fluorouracil 
followed by surgery versus up- front surgery in locally advanced 
resectable oral squamous cell carcinoma. J Clin Oncol 2012;30:1–12.
 24 Perrone F, Bossi P, Cortelazzi B, et al. Tp53 mutations and pathologic 
complete response to neoadjuvant cisplatin and fluorouracil 
chemotherapy in resected oral cavity squamous cell carcinoma. J 
Clin Oncol 2010;28:761–6.
 25 O’Quigley J, Pepe M, Fisher L. Continual reassessment method. 
Biometrics 1990;46:33–48.
 26 Cheung YK. Dose finding by the continual reassessment method. 
New York: Chapman & Hall/CRC Press, 2011.
 27 Cheung YK, Chappell R. Sequential designs for phase I clinical trials 
with late- onset toxicities. Biometrics 2000;56:1177–82.
 28 Yap C, Craddock C, Quigley JO, et al. Comparing the implementation 
of a modified continual reassessment method to a 3+3 design in a 
phase I acute myeloid leukaemia trial. Clin Trials 2013;10:75.
 29 Do K, Wilsker D, Ji J, KT D, Balasubramanian P, et al. Phase 
I study of single- agent AZD1775 (MK-1775), a Wee1 kinase 
inhibitor, in patients with refractory solid tumors. J Clin Oncol 
2015;33:3409–15.
 30 Schellens JH, Leijen S, Shapiro G, et al. Update on a phase I 
pharmacologic and pharmacodynamic study of MK1775, a WEE1 
tyrosine kinase inhibitor in monotherapy and combination with 
gemcitabine, cisplatin or carboplatin in patents with advance solid 
tumour. ASCO, 2011. Available: http:// meetinglibrary. asco. org/ 
content/ 62389
 31 Homma A, Inamura N, Oridate N, et al. Concomitant Weekly cisplatin 
and radiotherapy for head and neck cancer. Jpn J Clin Oncol 
2011;41:980–6.
 32 Traynor AM, Richards GM, Hartig GK, et al. Comprehensive IMRT 
plus Weekly cisplatin for advanced head and neck cancer: the 
University of Wisconsin experience. Head Neck 2010;32:599–606.
 33 Jagdis A, Laskin J, Hao D, et al. Dose delivery analysis of Weekly 
versus 3- weekly cisplatin concurrent with radiation therapy for 
locally advanced nasopharyngeal carcinoma (NPC). Am J Clin Oncol 
2014;37:63–9.
 34 Aaronson NK, Ahmedzai S, Bergman B, et al. The European 
organization for research and treatment of cancer QLQ- C30: a 
quality- of- life instrument for use in international clinical trials in 
oncology. J Natl Cancer Inst 1993;85:365–76.
 35 Bjordal K, de Graeff A, Fayers PM, et al. A 12 country field study of 
the EORTC QLQ- C30 (version 3.0) and the head and neck cancer 
specific module (EORTC QLQ- H&N35) in head and neck patients. 
EORTC Quality of Life Group. Eur J Cancer 2000;36:1796–807.
 36 Chen AY, Frankowski R, Bishop- Leone J, et al. The development 
and validation of a dysphagia- specific quality- of- life questionnaire 
for patients with head and neck cancer: the M. D. Anderson 
dysphagia inventory. Arch Otolaryngol Head Neck Surg 
2001;127:870–6.
 37 National Cancer Institute. Common terminology criteria for adverse 
events (CTCAE) (version 4.0). Available: http:// ctep. cancer. gov/ 
protocolDevelopment/ electronic_ applications/ ctc. htm copyright.
 o
n
 M
arch 18, 2020 at University of G
lasgow. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-033009 on 16 March 2020. Downloaded from 
